KemPharm's SDX Higher Dose Shows Potential Against Sleep Disorders
KemPharm Inc (NASDAQ: KMPH)
Benzinga ·
Get all your news in one place.
100's of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100's of premium titles. One news app.
The Latest Breaking News from KemPharm Inc
KemPharm To Develop KP1077 As Lead SDX Candidate For Chronic Sleep Disorder
KemPharm Inc (NASDAQ: KMPH) has selected KP1077 for idiopathic hypersomnia (IH) as its lead serdexmethylphenidate (SDX) candidate in the pipeline.
Benzinga ·
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Coverage From
Benzinga
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.
100+ trusted global sources.
